Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 3/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.50 |
| ▸ | MET | P08581 | 7/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396814 | 0.92 | PTK2B (0.53) | PTK2BPTK2FGFR2KDRPDGFRA | |
| SCHEMBL1396760 | 0.88 | PTK2B (0.57) | PTK2BPTK2KDRPDGFRAMET | |
| SCHEMBL4772866 | 0.88 | MET (0.49) | PTK2BPTK2FGFR2KDRPDGFRA | |
| SCHEMBL1396829 | 0.88 | PTK2B (0.52) | PTK2BPTK2FGFR2KDRPDGFRA | |
| SCHEMBL1396745 | 0.87 | PTK2B (0.53) | PTK2BPTK2FGFR2KDRPDGFRA | |
| SCHEMBL1396843 | 0.86 | PTK2B (0.58) | PTK2BPTK2FGFR2KDRPDGFRA | |
| SCHEMBL4776708 | 0.84 | PTK2B (0.49) | PTK2BPTK2FGFR2KDRPDGFRA | |
| SCHEMBL4777275 | 0.82 | PTK2B (0.48) | PTK2BPTK2FGFR2KDRPDGFRA | |
| SCHEMBL1396864 | 0.81 | PTK2B (0.57) | PTK2BPTK2KDRMETKIT | |
| SCHEMBL1396753 | 0.80 | PTK2B (0.55) | PTK2BPTK2KDRPDGFRAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | disclosed |